ABC | Volume 113, Nº3, Setembro 2019

Artigo Original Figueiredo et al. Febre reumática: uma doença sem cor Arq Bras Cardiol. 2019; 113(3):345-354 22. TaubertK,MarkoSB.Accesstoessentialmedicines: illuminatingdisparities in theglobalsupplyofbenzathinepenicillinG inthecontextofrheumatic fever/ rheumatic heart disease prevention. J AmColl Cardiol. 2013;61(10):E2004. 23. Müller RE. Estudo longitudinal de pacientes portadores de cardiopatia reumatica no Rio de Janeiro. [dissertaço]. Rio Janeiro: Ministerio da Saude/ FIOCRUZ; 2008. 24. Watkins DA, Mvundura M, Nordet P, Mayosi BM. A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba. PLoS One. 2015;10(3):e0121363. 25. Musuku J, Lungu JC, Machila E, Jones C, Colin L, Schwaninger S, et al. Epidemiology of pharyngitis as reported by Zambian school children and their families: implications for demand-side interventions to prevent rheumatic heart disease. BMC Infect Dis. 2017;17(1):473. 26. Spina GS. Febre Reumática. Título de especialista em cardiologia. 2nd ed. São Paulo: NVersos; 2014. 27. Nascimento BR, Sable C, Nunes MCP, Diamantino AC, Oliveira KKB, Oliveira CM, et al. Comparison between different strategies of rheumatic heart disease echocardiographic screening in Brazil: data from the PROVAR (Rheumatic Valve Disease Screening Program) study. J Am Heart Assoc. 2018;7(4):pii:e008039. 28. LibbyP,BonowRO,MannDL,ZipesDP,eds.Braunwald:Tratadodedoenças cardiovasculares. 10th ed. São Paulo: Elsevier; 2017. 29. Mirabel M, Bacquelin R, Tafflet M, Robillard C, Huon B, Corsenac P, et al. Screening for rheumatic heart disease: evaluation of a focused cardiac ultrasound approach. Circ Cardiovasc Imaging. 2015;8(1):pii:e002324. 30. ColquhounSM,CarapetisJR,KadoJH,SteerAC.Rheumaticheartdiseaseand its control in the Pacific. Expert Rev Cardiovasc Ther. 2009;7(12):1517-24. 31. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953-64. 32. Wyber R, Zühlke L, Carapetis J. The case for global investment in rheumatic heart-disease control. Bull World Health Organ. 2014;92(10):768-70. 33. Ralph AP, Fittock M, Schultz R, Thompson D, Dowden M, Clemens T, et al. Improvement in rheumatic fever and rheumatic heart diseasemanagement andpreventionusingahealthcentre-basedcontinuousquality improvement approach. BMC Heal Serv Res. 2013 Dec 18;13:525. 34. Islam AK, Majumder AA. Rheumatic fever and rheumatic heart disease in Bangladesh: a review. Indian Heart J. 2016;68(1):88-98. 35. Watkins D, Lubinga SJ, Mayosi B, Babigumira JB. A cost-effectiveness tool to guide the prioritization of interventions for rheumatic fever and rheumatic heart disease control in African Nations. PLoS Negl Trop Dis. 2016;10(8):e0004860. 36. Watkins D, Zuhlke L, Engel M, Daniels R, Francis V, Shaboodien G, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué. Cardiovasc J Afr. 2016;27(3):184-7. 37. Brasil. Ministério da Saúde. Instituto Nacional do Câncer. Posicionamento do Ministério da Saúde acerca da integridadade da saúde do homem no contexto do Novembro Azul. Nota Técnica Conjunta 2015. [acesso em 08 fev 2018]. Disponível em: http://portalarquivos2.saude.gov.br/images/ pdf/2015/novembro/09/Integralidade-sa--de-homens.pdf 38. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012;133(2):799-804. 39. Watkins DA, Roth GA. Global burden of rheumatic heart disease. N Engl J Med. 2018;378(1):e2. 40. Santos JPA, CarmoGALD , Beaton AZ, Lourenço TV, Diamantino AC, Nunes MDCP, et al. Challenges for the implementation of the first large-scale rheumatic heart disease screening program in Brazil: the PROVAR study experience. Arq Bras Cardiol. 2017;108(4):370-4. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 354